Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

This is an interventional diagnostic trial for Prostate Cancer focused on measuring Prostate Cancer, Stage I-III prostate adenocarcinoma Read More

Inclusion Criteria:

• Participants must have histologically confirmed prostate cancer.
• PSA level and prostate biopsy must be reviewed at Brigham and Women's Hospital or the Dana Farber Cancer Institute and should support a diagnosis of stage I-III prostate adenocarcinoma.
• Candidates with PSA greater than 20, digital rectal exam consistent with disease outside the prostate (clinical T3/T4 disease), or Gleason score 8 or greater, should have a bone scan and diagnostic pelvic CT or MRI to exclude metastatic disease.
• Prostate biopsy, serum PSA measurement, and any indicated diagnostic imaging studies must be performed within 60 days of the date of registration.
• Participants should not have had prior curative local treatment for prostate cancer, including no radiotherapy or prostatectomy. A maximum 90 days of systemic androgen deprivation therapy prior to registration is allowed.
• Participation is limited to adult patients, age 18 years or older.
• ECOG performance status ≥2 (Karnofsky ≥60%)
• Life expectancy of greater than 10 years.
• Able to tolerate an MRI examination.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Participants with known or suspected metastatic (stage IV) prostate cancer.
• Participants with an implanted device, prosthesis, or any other foreign body with ferromagnetic properties that would make them ineligible to undergo MRI examination.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.